Cognitive Impairment - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 243 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cognitive Impairment - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H1 2015’, provides an overview of the Cognitive Impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Cognitive Impairment Overview 11
Therapeutics Development 12
Pipeline Products for Cognitive Impairment - Overview 12
Pipeline Products for Cognitive Impairment - Comparative Analysis 13
Cognitive Impairment - Therapeutics under Development by Companies 14
Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 19
Cognitive Impairment - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Cognitive Impairment - Products under Development by Companies 23
Cognitive Impairment - Products under Investigation by Universities/Institutes 29
Cognitive Impairment - Companies Involved in Therapeutics Development 30
AbbVie Inc. 30
Addex Therapeutics Ltd 31
AGY Therapeutics, Inc. 32
Amarantus Bioscience Holdings, Inc. 33
AstraZeneca PLC 34
Avineuro Pharmaceuticals, Inc. 35
Boehringer Ingelheim GmbH 36
Bristol-Myers Squibb Company 37
Cardax Pharmaceuticals, Inc. 38
CoMentis, Inc. 39
D-Pharm Ltd. 40
Dart NeuroScience LLC 41
Eisai Co., Ltd. 42
Eli Lilly and Company 43
Evotec AG 44
F. Hoffmann-La Roche Ltd. 45
FORUM Pharmaceuticals Inc. 46
H. Lundbeck A/S 47
Heptares Therapeutics Ltd. 48
Intra-Cellular Therapies, Inc. 49
Iproteos S.L. 50
Merck & Co., Inc. 51
Mithridion, Inc. 52
Mnemosyne Pharmaceuticals, Inc. 53
Neuralstem, Inc. 54
Novartis AG 55
Octapharma AG 56
Omeros Corporation 57
Pacific Northwest Biotechnology, LLC 58
Panacea Pharmaceuticals, Inc. 59
Pfizer Inc. 60
Pherin Pharmaceuticals, Inc. 61
Sage Therapeutics 62
Saniona AB 63
Sanofi 64
Shire Plc 65
Siena Biotech S.p.A. 66
SK Biopharmaceuticals Co., Ltd. 67
Sunovion Pharmaceuticals Inc. 68
Suven Life Sciences Ltd. 69
Takeda Pharmaceutical Company Limited 70
Teva Pharmaceutical Industries Limited 71
Theratechnologies Inc. 72
Upsher-Smith Laboratories, Inc. 73
Vicore Pharma AB 74
Virogenomics, Inc. 75
Cognitive Impairment - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Target 77
Assessment by Mechanism of Action 80
Assessment by Route of Administration 83
Assessment by Molecule Type 85
Drug Profiles 87
2-PMPA - Drug Profile 87
A-431404 - Drug Profile 88
ADX-92639 - Drug Profile 89
AN-761 - Drug Profile 90
AP-61 - Drug Profile 91
AQW-051 - Drug Profile 92
AUT-1 - Drug Profile 93
AUT-6 - Drug Profile 94
AUT-9 - Drug Profile 95
AVL-3288 - Drug Profile 96
AVN-211 - Drug Profile 97
BAN-2401 - Drug Profile 98
BCA-909 - Drug Profile 100
BI-409306 - Drug Profile 102
BMS-933043 - Drug Profile 103
BNC-375 - Drug Profile 104
C-21 - Drug Profile 105
CDD-0304 - Drug Profile 107
CDX-085 - Drug Profile 109
CSP-1103 - Drug Profile 111
DAOI-B - Drug Profile 113
DP-NDD - Drug Profile 114
Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment - Drug Profile 115
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 116
DSP-3748 - Drug Profile 117
E-1R - Drug Profile 118
eltoprazine - Drug Profile 119
encenicline hydrochloride - Drug Profile 121
erteberel - Drug Profile 124
EVT-501 - Drug Profile 125
FRM-0962 - Drug Profile 126
GTS-21 - Drug Profile 127
HTL-9936 - Drug Profile 129
idursulfase - Drug Profile 130
immune globulin (human) - Drug Profile 131
IPR-001 - Drug Profile 133
IPR-088 - Drug Profile 134
IPR-19 - Drug Profile 135
irdabisant - Drug Profile 136
ITI-214 - Drug Profile 137
ladostigil tartrate - Drug Profile 138
levetiracetam - Drug Profile 140
LUAF-64280 - Drug Profile 141
LY-3002813 - Drug Profile 142
NS-9283 - Drug Profile 143
NSI-189 - Drug Profile 145
PAN-811 - Drug Profile 146
Peptide T - Drug Profile 148
PF-04958242 - Drug Profile 149
PH-15 - Drug Profile 150
PNU-120596 - Drug Profile 151
RO-4938581 - Drug Profile 152
roflumilast - Drug Profile 153
RTL-551 - Drug Profile 156
SAGE-547 - Drug Profile 157
SAR-228810 - Drug Profile 159
SEN-15924 - Drug Profile 160
SKL-15508 - Drug Profile 161
Small Molecule 1 for Cognitive Impairment - Drug Profile 162
Small Molecule 10 for Cognitive Impairment - Drug Profile 163
Small Molecule 11 for Cognitive Impairment - Drug Profile 164
Small Molecule 12 for Cognitive Impairment - Drug Profile 165
Small Molecule 2 for Cognitive Impairment - Drug Profile 166
Small Molecule 3 for Cognitive Impairment - Drug Profile 167
Small Molecule 4 for Cognitive Impairment - Drug Profile 168
Small Molecule 5 for Cognitive Impairment - Drug Profile 169
Small Molecule 6 for Cognitive Impairment - Drug Profile 170
Small Molecule 7 for Cognitive Impairment - Drug Profile 171
Small Molecule 8 for Cognitive Impairment - Drug Profile 172
Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile 173
Small Molecule to Agonize NMDA2B for CIAS - Drug Profile 174
Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile 176
Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile 177
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 178
Small Molecule to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia - Drug Profile 179
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 180
Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer - Drug Profile 181
Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 182
Small Molecules to Agonize 5-HT4 Receptors for Cognitive Impairment - Drug Profile 183
Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile 184
Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile 185
Small Molecules to Agonize nAChR for Alzheimer's Disease and Cognitive Impairment - Drug Profile 186
Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile 188
Small Molecules to Inhibit Tyrosine Phosphatase for Cognition and Schizophrenia - Drug Profile 189
Stem Cell Therapy for Cognitive Impairment - Drug Profile 190
SUVN-501 - Drug Profile 191
SUVN-901 - Drug Profile 192
SUVN-976 - Drug Profile 193
SUVN-D-1108121 - Drug Profile 194
TAK-058 - Drug Profile 195
tesamorelin acetate - Drug Profile 196
tropisetron hydrochloride - Drug Profile 199
VU-0092273 - Drug Profile 200
xamoterol fumarate - Drug Profile 201
Cognitive Impairment - Recent Pipeline Updates 202
Cognitive Impairment - Dormant Projects 224
Cognitive Impairment - Discontinued Products 230
Cognitive Impairment - Product Development Milestones 231
Featured News & Press Releases 231
Appendix 236
Methodology 236
Coverage 236
Secondary Research 236
Primary Research 236
Expert Panel Validation 236
Contact Us 236
Disclaimer 237

List of Tables

Number of Products under Development for Cognitive Impairment, H1 2015 18
Number of Products under Development for Cognitive Impairment - Comparative Analysis, H1 2015 19
Number of Products under Development by Companies, H1 2015 21
Number of Products under Development by Companies, H1 2015 (Contd..1) 22
Number of Products under Development by Companies, H1 2015 (Contd..2) 23
Number of Products under Development by Companies, H1 2015 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Products under Development by Companies, H1 2015 29
Products under Development by Companies, H1 2015 (Contd..1) 30
Products under Development by Companies, H1 2015 (Contd..2) 31
Products under Development by Companies, H1 2015 (Contd..3) 32
Products under Development by Companies, H1 2015 (Contd..4) 33
Products under Development by Companies, H1 2015 (Contd..5) 34
Products under Investigation by Universities/Institutes, H1 2015 35
Cognitive Impairment - Pipeline by AbbVie Inc., H1 2015 36
Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H1 2015 37
Cognitive Impairment - Pipeline by AGY Therapeutics, Inc., H1 2015 38
Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 39
Cognitive Impairment - Pipeline by AstraZeneca PLC, H1 2015 40
Cognitive Impairment - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 41
Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H1 2015 42
Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H1 2015 43
Cognitive Impairment - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 44
Cognitive Impairment - Pipeline by CoMentis, Inc., H1 2015 45
Cognitive Impairment - Pipeline by D-Pharm Ltd., H1 2015 46
Cognitive Impairment - Pipeline by Dart NeuroScience LLC, H1 2015 47
Cognitive Impairment - Pipeline by Eisai Co., Ltd., H1 2015 48
Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2015 49
Cognitive Impairment - Pipeline by Evotec AG, H1 2015 50
Cognitive Impairment - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 51
Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 52
Cognitive Impairment - Pipeline by H. Lundbeck A/S, H1 2015 53
Cognitive Impairment - Pipeline by Heptares Therapeutics Ltd., H1 2015 54
Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 55
Cognitive Impairment - Pipeline by Iproteos S.L., H1 2015 56
Cognitive Impairment - Pipeline by Merck & Co., Inc., H1 2015 57
Cognitive Impairment - Pipeline by Mithridion, Inc., H1 2015 58
Cognitive Impairment - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 59
Cognitive Impairment - Pipeline by Neuralstem, Inc., H1 2015 60
Cognitive Impairment - Pipeline by Novartis AG, H1 2015 61
Cognitive Impairment - Pipeline by Octapharma AG, H1 2015 62
Cognitive Impairment - Pipeline by Omeros Corporation, H1 2015 63
Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H1 2015 64
Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 65
Cognitive Impairment - Pipeline by Pfizer Inc., H1 2015 66
Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H1 2015 67
Cognitive Impairment - Pipeline by Sage Therapeutics, H1 2015 68
Cognitive Impairment - Pipeline by Saniona AB, H1 2015 69
Cognitive Impairment - Pipeline by Sanofi, H1 2015 70
Cognitive Impairment - Pipeline by Shire Plc, H1 2015 71
Cognitive Impairment - Pipeline by Siena Biotech S.p.A., H1 2015 72
Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 73
Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 74
Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H1 2015 75
Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 76
Cognitive Impairment - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 77
Cognitive Impairment - Pipeline by Theratechnologies Inc., H1 2015 78
Cognitive Impairment - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 79
Cognitive Impairment - Pipeline by Vicore Pharma AB, H1 2015 80
Cognitive Impairment - Pipeline by Virogenomics, Inc., H1 2015 81
Assessment by Monotherapy Products, H1 2015 82
Number of Products by Stage and Target, H1 2015 84
Number of Products by Stage and Mechanism of Action, H1 2015 87
Number of Products by Stage and Route of Administration, H1 2015 90
Number of Products by Stage and Molecule Type, H1 2015 92
Cognitive Impairment Therapeutics - Recent Pipeline Updates, H1 2015 208
Cognitive Impairment - Dormant Projects, H1 2015 230
Cognitive Impairment - Dormant Projects (Contd..1), H1 2015 231
Cognitive Impairment - Dormant Projects (Contd..2), H1 2015 232
Cognitive Impairment - Dormant Projects (Contd..3), H1 2015 233
Cognitive Impairment - Dormant Projects (Contd..4), H1 2015 234
Cognitive Impairment - Dormant Projects (Contd..5), H1 2015 235
Cognitive Impairment - Discontinued Products, H1 2015 236